The Chernecky clinical data is an addition to the growing body of evidence associating various negative and positive displacement split-septum and mechanical valves with increased rates of complications, whether catheter-related bloodstream infections or intraluminal thrombotic occlusions.
"Evidence-based occlusion studies are rare, especially in outpatient pediatric oncology populations. Reducing and/or eliminating occlusions will negate treatment delays, add time to nursing and physician care, decrease cost, decrease mortalities and increase the quality of life for patients and their family. This is a clear evaluation and indication by the numbers that the InVision-Plus® is the best needleless IV connector for patients," said Dana Wm. Ryan, President and CEO, RyMed Technologies.
About RyMed Technologies, Inc.
Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company's products are designed to help reduce catheter-related bloodstream infections (CR-BSIs) and intraluminal thrombotic catheter occlusions associated with needleless IV connectors. More than 10 years of research and development have gone into InVision-Plus® IV Connector. In January, 2011 the Company introduced the first chlorhexidine/silver ion technology with the new InVision-Plus® CS™. For more information, call (615) 790-8093 or access www.rymedtech.com.
|SOURCE RyMed Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved